Northwest & Ethical Investments’s Akero Therapeutics AKRO Stock Holding History

Northwest & Ethical Investments’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,700	Closed	-$176K	–	502
2025 Q3	$176K	Hold	3,700	–	–	﹤0.01%	469
2025 Q2	$208K	Buy	3,700 +2,900	+363%	+$132K	0.01%	450
2025 Q1	$32.3K	Buy	+800	New	+$33.9K	﹤0.01%	469

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Northwest & Ethical Investments's AKRO Position: Q4 2025 in Review

Northwest & Ethical Investments sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 3,700 shares — an estimated $176K sold.

Northwest & Ethical Investments first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $208K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Northwest & Ethical Investments reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Northwest & Ethical Investments sold 3,700 Akero Therapeutics shares in Q4 2025, an estimated $176K.
Northwest & Ethical Investments first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
Northwest & Ethical Investments's Akero Therapeutics position peaked at $208K in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Northwest & Ethical Investments's 13F filing for Q4 2025, filed 12 Feb 2026.